Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Type 2 diabetes mellitus (T2DM) is associated with increased risk of cardiovascular disease and nephropathy—now the leading cause of end-stage renal disease and dialysis in Europe and the United States. Inflammation and oxidative stress play a pivotal role in the development of diabetic complication...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2016-01-01
|
Series: | Journal of Diabetes Research |
Online Access: | http://dx.doi.org/10.1155/2016/5147468 |
id |
doaj-9c9faf780e484ebfbc1ec562174daab3 |
---|---|
record_format |
Article |
spelling |
doaj-9c9faf780e484ebfbc1ec562174daab32020-11-24T23:14:54ZengHindawi LimitedJournal of Diabetes Research2314-67452314-67532016-01-01201610.1155/2016/51474685147468Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsLuminita Voroneanu0Ionut Nistor1Raluca Dumea2Mugurel Apetrii3Adrian Covic4Nephrology Department, Faculty of Medicine, University of Medicine and Pharmacy “Gr. T. Popa”, 700503 Iasi, RomaniaNephrology Department, Faculty of Medicine, University of Medicine and Pharmacy “Gr. T. Popa”, 700503 Iasi, RomaniaNephrology Department, Faculty of Medicine, University of Medicine and Pharmacy “Gr. T. Popa”, 700503 Iasi, RomaniaNephrology Department, Faculty of Medicine, University of Medicine and Pharmacy “Gr. T. Popa”, 700503 Iasi, RomaniaNephrology Department, Faculty of Medicine, University of Medicine and Pharmacy “Gr. T. Popa”, 700503 Iasi, RomaniaType 2 diabetes mellitus (T2DM) is associated with increased risk of cardiovascular disease and nephropathy—now the leading cause of end-stage renal disease and dialysis in Europe and the United States. Inflammation and oxidative stress play a pivotal role in the development of diabetic complications. Silymarin, an herbal drug with antioxidant and anti-inflammatory properties, may improve glycemic control and prevent the progression of the complications. In a systematic review and meta-analysis including five randomized controlled trials and 270 patients, routine silymarin administration determines a significant reduction in fasting blood glucose levels (−26.86 mg/dL; 95% CI −35.42–18.30) and HbA1c levels (−1.07; 95% CI −1.73–0.40) and has no effect on lipid profile. Benefits for silymarin on proteinuria and CKD progressions are reported in only one small study and are uncertain. However, being aware of the low quality of the available evidence and elevated heterogeneity of these studies, no recommendation can be made and further studies are needed.http://dx.doi.org/10.1155/2016/5147468 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Luminita Voroneanu Ionut Nistor Raluca Dumea Mugurel Apetrii Adrian Covic |
spellingShingle |
Luminita Voroneanu Ionut Nistor Raluca Dumea Mugurel Apetrii Adrian Covic Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Journal of Diabetes Research |
author_facet |
Luminita Voroneanu Ionut Nistor Raluca Dumea Mugurel Apetrii Adrian Covic |
author_sort |
Luminita Voroneanu |
title |
Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
title_short |
Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
title_full |
Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
title_fullStr |
Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
title_full_unstemmed |
Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
title_sort |
silymarin in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials |
publisher |
Hindawi Limited |
series |
Journal of Diabetes Research |
issn |
2314-6745 2314-6753 |
publishDate |
2016-01-01 |
description |
Type 2 diabetes mellitus (T2DM) is associated with increased risk of cardiovascular disease and nephropathy—now the leading cause of end-stage renal disease and dialysis in Europe and the United States. Inflammation and oxidative stress play a pivotal role in the development of diabetic complications. Silymarin, an herbal drug with antioxidant and anti-inflammatory properties, may improve glycemic control and prevent the progression of the complications. In a systematic review and meta-analysis including five randomized controlled trials and 270 patients, routine silymarin administration determines a significant reduction in fasting blood glucose levels (−26.86 mg/dL; 95% CI −35.42–18.30) and HbA1c levels (−1.07; 95% CI −1.73–0.40) and has no effect on lipid profile. Benefits for silymarin on proteinuria and CKD progressions are reported in only one small study and are uncertain. However, being aware of the low quality of the available evidence and elevated heterogeneity of these studies, no recommendation can be made and further studies are needed. |
url |
http://dx.doi.org/10.1155/2016/5147468 |
work_keys_str_mv |
AT luminitavoroneanu silymarinintype2diabetesmellitusasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT ionutnistor silymarinintype2diabetesmellitusasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT ralucadumea silymarinintype2diabetesmellitusasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT mugurelapetrii silymarinintype2diabetesmellitusasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT adriancovic silymarinintype2diabetesmellitusasystematicreviewandmetaanalysisofrandomizedcontrolledtrials |
_version_ |
1725592782818508800 |